Results 21 to 30 of about 2,507,641 (307)

Bayesian network meta-analysis of efficacy and safety of neoadjuvant therapy for non-small-cell lung cancer

Therapeutic Advances in Medical Oncology, 2020
Objective: Neoadjuvant chemotherapy has increased the survival benefit of non-small cell lung cancer (NSCLC) patients. The effects of different neoadjuvant therapies are still controversial. We carried out the study to evaluate the efficacy and safety of
Yijiu Ren, Hai Tang, Jie Zhang, Yunlang She, Xiaoting Sun, Dong Xie, Chang Chen   +6 more
doaj   +1 more source

Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer

Frontiers in Immunology, 2023
ObjectivesRecent clinical studies have demonstrated that immunotherapy-based neoadjuvant therapy have promising effectiveness for patients with resectable non-small cell lung cancer (NSCLC) in terms of pathologic response.
Jie Shen, Linping Gu, Yuwen Qi, Yaxian Yao, Shun Lu, Zhiwei Chen   +5 more
doaj   +1 more source

A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial [PDF]

, 2013
Background: Neo-tAnGo, a National Cancer Research Network (NCRN) multicentre randomised neoadjuvant chemotherapy trial in early breast cancer, enroled 831 patients in the United Kingdom.
K Walland, N Fenwick, M Iddawela, E Provenzano, Walland, K., Abraham, J. (Janet), Grier, Anna, L Hiller, J Abraham, A Grier, Fenwick, Nicola, Bowden, S. (Sarah), Iddawela, M., Caldas, C., H M Earl, R Champ, S Bowden, J Dunn, Vallier, A. -L., Champ, R., Earl, Helena M., C Caldas, Dunn, Janet A., Hiller, Louise, A-L Vallier, Provenzano, E.   +25 more
core   +2 more sources

Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma

, 2023
Pancreatic ductal adenocarcinoma (PDAC) is a challenging disease process with a 5-year survival rate of only 11%. Neoadjuvant therapy in patients with localized pancreatic cancer has multiple theoretical benefits, including improved patient selection for
Anish J. Jain, Matthew H. G. Katz, Jessica E. Maxwell, Rebecca A. Snyder   +3 more
core   +1 more source

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction [PDF]

, 2013
Background: This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric ...
Klautke, Gunther, Galle, Peter R., Brenner, Baruch, Arnold, Dirk, Roessler, Hans-Peter, Thomaidis, Thomas, Schimanski, Carl Christoph, Schmidberger, Heinz, Rödel, Claus, Gockel, Ines, Möhler, Markus, Trarbach, Tanja, Lang, Hauke   +12 more
core   +1 more source

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer [PDF]

, 2013
Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas
Jens Huober, Reinisch, Mattea, Sibylle Loibl, Silvia Darb-Esfahani, Michael Untch, Hans Tesch, Martin-Leo Hansmann, Jan C Brase, Knut Engels, Judith Prinzler, Keyur Mehta, Minckwitz, Gunter von, Brase, Jan C., Kronenwett, Ralf, Hansmann, Martin-Leo, Huober, Jens, Engels, Knut, Solbach, Christine, Tesch, Hans, Carsten Denkert, Denkert, Carsten, Gunter von Minckwitz, Bruno V Sinn, Loibl, Sibylle, Mattea Reinisch, Peter A Fasching, Sinn, Bruno V., Ralf Kronenwett, Christine Solbach, Prinzler, Judith, Mehta, Keyur, Fasching, Peter Andreas, Untch, Michael, Denkert, Carsten Michael, Darb-Esfahani, Silvia   +34 more
core   +2 more sources

Expert consensus on neoadjuvant treatment of breast cancer in China (2022 edition)

Zhongguo aizheng zazhi, 2022
Neoadjuvant therapy has become one of the standard treatments in early breast cancer. In 2019, China breast cancer neoadjuvant therapy expert group discussed and expounded the purpose, indication, evaluation criteria, surgical operation principles and ...
Expert group of expert consensus on neoadjuvant treatment of breast cancer in China (2022 edition)
doaj  

Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma

npj Breast Cancer, 2021
Neoadjuvant therapy in breast cancer can downstage axillary lymph nodes and reduce extent of axillary surgery. As such, accurate determination of nodal status after neoadjuvant therapy and before surgery impacts surgical management. There are scarce data
Mary Kathryn Abel, Heather Greenwood, Tatiana Kelil, Ruby Guo, Case Brabham, Nola Hylton, Jasmine Wong, Michael Alvarado, Cheryl Ewing, Laura J. Esserman, Judy C. Boughey, Rita A. Mukhtar   +11 more
doaj   +1 more source

Comparison of prognosis between neoadjuvant imatinib and upfront surgery for GIST: A systematic review and meta-analysis

Frontiers in Pharmacology, 2022
Background: Significant survival benefit of adjuvant imatinib therapy has been observed in gastrointestinal stromal tumor (GIST). However, the impact of neoadjuvant imatinib on prognosis of GIST remains unclear.
Zhen Liu, Zimu Zhang, Juan Sun, Jie Li, Ziyang Zeng, Mingwei Ma, Xin Ye, Fan Feng, Weiming Kang   +8 more
doaj   +1 more source

Management of inoperable endometrial cancer [PDF]

Obstetrics & Gynecology Science, 2022
Some endometrial cancer (EMC) patients are not good candidates for primary surgery. The three major types of treatment for inoperable EMC are radiation therapy, chemotherapy, or their combination as neoadjuvant treatment before surgery. Radiation therapy
Supakorn Pitakkarnkul, Saranya Chanpanitkitchot, Siriwan Tangjitgamol   +2 more
doaj   +1 more source